> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-66/
- Published: 2022-01-23T12:00:00.000Z
- Updated: 2026-09-14T17:29:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150987

**FDA Seeks Comments on Covid Guidances**  
1/21/2022 *Federal Register* notice: FDA is announcing recent guidance documents related to the Covid-19 public health emergency. Under emergency procedures, the documents have been implemented without prior comment, but they remain subject to comment in accordance with the agency’s good guidance practices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-21/pdf/2022-01146.pdf?ref=fdaweb.com).  

**Draft Guide on 702(b) FDA Samples**  
1/21/2022 *Federal Register* notice: FDA is making available a draft guidance entitled *Collecting and Providing 702(b) Portions of FDA Official Samples — Questions and Answers*. Under Section 702(b) of the FD&C Act, when FDA collects a sample of a food, drug, or cosmetic for analysis, FDA must, upon request, provide a part of such official sample for examination or analysis by any person named on the label of the article, or the owner thereof, or his attorney or agent. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-21/pdf/2022-01143.pdf?ref=fdaweb.com).  

**FDA Revokes 5 Covid Test EUAs**  
1/21/2022 *Federal Register* notice: FDA is announcing the revocation of the Emergency Use Authorizations (EUAs) issued to Cellex Inc. for the Cellex q–SARS–CoV–2 IgG/IgMRapid Test, BioMerieux SA for the SARS–COV–2 R–GENE, Siemens Healthcare Diagnostics Inc. for the Atellica IM SARS–CoV–2 IgG (COV2G), Siemens Healthcare Diagnostics Inc. for the Advia Centaur SARS–CoV–2 IgG, and Cepheid for the XpertOmni SARS–CoV–2\. FDA revoked the EUAs after the companies notified it that the tests were no longer marketed, distributed or supported and requested they be revoked. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-21/pdf/2022-01139.pdf?ref=fdaweb.com).  

**Proposal to Classify Certain Antigen Devices in Class 2**  
1/20/2022 *Federal Register* notice: FDA is seeking comments on its proposal to classify human leukocyte antigen, human platelet antigen, and human neutrophil antigen devices into Class 2 (special controls). The agency says it does not intend to exempt these device types from premarket notification requirements. After considering comments, FDA will publish a final regulation classifying the device types. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-01156.pdf?ref=fdaweb.com).  

**FDA Corrects Notice on ANDA Withdrawal**  
1/18/2022 *Federal Register* notice: FDA is correcting a 10/22/2021 notice that announced the withdrawal of 216 ANDAs. The document was published with an incorrect date, and it wrongly indicated that Bio-Nucleonics’ ANDA 075941 for strontium chloride SR–89 injection was being withdrawn. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-18/pdf/2022-00831.pdf?ref=fdaweb.com).